At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PFSA Profusa Inc
Closed 04-06 16:00:00 EDT
1.85
+1.09
+144.06%
盘后1.51
-0.34-18.38%
19:59 EDT
High2.25Low1.72Vol240.96M
Open1.92D1 Closing0.7580Amplitude69.92%
Mkt Cap2.51MTradable Cap2.51MTotal Shares1.36M
T/O431.52MT/O Rate17,725.76%Tradable Shares1.36M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali
Reuters  ·  01:51
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali
BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget
Reuters  ·  04-06 23:44
BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget
BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis
Reuters  ·  04-06 21:14
BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis
BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa
Reuters  ·  04-06 19:56
BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa
BRIEF-Profusa Expands Into Multi-Billion Dollar Precision Diagnostics Market With $30M Letter Of Intent For A Panomics Platform
Reuters  ·  04-06 18:45
BRIEF-Profusa Expands Into Multi-Billion Dollar Precision Diagnostics Market With $30M Letter Of Intent For A Panomics Platform
Profusa signs LOI to acquire BioInsights’ PanOmics platform for $30 million in stock
Reuters  ·  04-06 18:01
Profusa signs LOI to acquire BioInsights’ PanOmics platform for $30 million in stock
Profusa Expands Into Multi-Billion Dollar Precision Diagnostics Market With $30M Letter of Intent for a Panomics Platform
THOMSON REUTERS  ·  04-06 18:00
Profusa Expands Into Multi-Billion Dollar Precision Diagnostics Market With $30M Letter of Intent for a Panomics Platform
Profusa Inc - Under Letter of Intent, Bioinsights to Receive 3% Royalty on Net Revenue
THOMSON REUTERS  ·  04-06 18:00
Profusa Inc - Under Letter of Intent, Bioinsights to Receive 3% Royalty on Net Revenue
Profusa delays annual report filing, expects 10-K within 15-day extension
Reuters  ·  04-01
Profusa delays annual report filing, expects 10-K within 15-day extension
BRIEF-Profusa Inc - Enters Amendment To Promissory Note With Northview Sponsor I LLC On March 20, 2026 - SEC Filing
Reuters  ·  03-27
BRIEF-Profusa Inc - Enters Amendment To Promissory Note With Northview Sponsor I LLC On March 20, 2026 - SEC Filing
Profusa Inc - Extends Maturity Date of Promissory Note to December 31, 2026 - SEC Filing
THOMSON REUTERS  ·  03-27
Profusa Inc - Extends Maturity Date of Promissory Note to December 31, 2026 - SEC Filing
Profusa extends promissory note maturity to December 31, 2026 due to amendment with NorthView Sponsor I
Reuters  ·  03-27
Profusa extends promissory note maturity to December 31, 2026 due to amendment with NorthView Sponsor I
Profusa Inc - Terminates Bitcoin Treasury Reserve Strategy and to Liquidate Bitcoin Holdings - SEC Filing
THOMSON REUTERS  ·  03-13
Profusa Inc - Terminates Bitcoin Treasury Reserve Strategy and to Liquidate Bitcoin Holdings - SEC Filing
Profusa Plans to End Bitcoin Treasury Reserve Strategy and Liquidate Its Bitcoin Holdings, Leading to Termination of Related Custody Control Agreement
Reuters  ·  03-13
Profusa Plans to End Bitcoin Treasury Reserve Strategy and Liquidate Its Bitcoin Holdings, Leading to Termination of Related Custody Control Agreement
Profusa Withdraws S-1 Registration Statement and Plans Smaller Offering
Reuters  ·  02-27
Profusa Withdraws S-1 Registration Statement and Plans Smaller Offering
Profusa: Offering to Support Near-Term Projected Europe Lumee Oxygen Product Revenue Starting Q2 2026
THOMSON REUTERS  ·  02-27
Profusa: Offering to Support Near-Term Projected Europe Lumee Oxygen Product Revenue Starting Q2 2026
Profusa Inc - Will Not Proceed With Public Offering
THOMSON REUTERS  ·  02-27
Profusa Inc - Will Not Proceed With Public Offering
Profusa to Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
THOMSON REUTERS  ·  02-27
Profusa to Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
THOMSON REUTERS  ·  02-19
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
Profusa Raises 2026 Revenue Guidance to $1.5M-$3M
Reuters  ·  02-19
Profusa Raises 2026 Revenue Guidance to $1.5M-$3M

Introduction

Company Name.
Profusa Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Issue price:
--